5 news items
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
CNTB
22 May 24
functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company's lead product candidate
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
CNTB
7 May 24
and discover potent product candidates against validated immune targets. The Company's lead product candidate, rademikibart (formerly known as CBP-201
HC Wainwright & Co. Maintains Buy on Connect Biopharma Hldgs, Raises Price Target to $8
CNTB
17 Apr 24
HC Wainwright & Co. analyst Emily Bodnar maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and raises the price target from $7 to $8.
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
CNTB
16 Apr 24
), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001). J
HC Wainwright & Co. Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $7
CNTB
4 Mar 24
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and announces Price Target of $7.
- Prev
- 1
- Next